OCUL as reported
Ocular Therapeutix, Inc. reported $52M of revenue over the trailing twelve months, −13% on the year before. 10 reported series are charted on this page, each one as filed.
$52M
Revenue, trailing twelve months · to Q1 2026 · −13% against the twelve months before
- Net Income
- −$290M
Net Income · +51% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$241M
Free Cash Flow · +62% year on year · trailing twelve months to Q1 2026
- Op Margin
- −592%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $52M | −13% | Q1 2026 |
| Net Income | −$290M | +51% | Q1 2026 |
| EPS | −$1.44 | +26% | Q1 2026 |
| Gross Margin | 87% | n/a | Q1 2026 |
| Op Margin | −592% | n/a | Q1 2026 |
| Net Margin | −573% | n/a | Q1 2026 |
| ROE | −65% | n/a | Q1 2026 |
| ROA | −45% | n/a | Q1 2026 |
| ROIC | 59% | n/a | Q3 2021 · 18 quarters behind |
| Free Cash Flow | −$241M | +62% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Ocular Therapeutix, Inc. (OCUL) - Revenue & ProfitRevenue & ProfitOcular Therapeutix, Inc. (OCUL)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com